-
公开(公告)号：US20140187557A1
公开(公告)日：2014-07-03
申请号：US14202136
申请日：2014-03-10
Applicant: Janssen Pharmaceutica NV
Inventor： Bruno Schoentjes , Alain Philippe Poncelet , Julien Georges Pierre-Olivier Doyon , Joannes Theodorus Maria Linders , Lieven Meerpoel , Luc August Laurentius Ver Donck
IPC: C07C215/42 , C07D313/08 , C07D405/04 , C07D213/53 , C07C217/74 , C07D295/16 , C07D213/65 , C07D239/26 , C07D215/14 , C07D317/58 , C07D295/096 , C07D207/06
CPC classification number: C07C215/42 , C07C35/52 , C07C43/192 , C07C215/64 , C07C217/08 , C07C217/74 , C07C2602/12 , C07D207/06 , C07D213/53 , C07D213/65 , C07D215/14 , C07D239/26 , C07D295/092 , C07D295/096 , C07D295/16 , C07D313/08 , C07D317/58 , C07D405/04 , C07D407/04
Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof.The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.
Abstract translation: 本发明涉及包括其任何立体化学异构体形式的式（I）化合物，其中取代基如说明书和权利要求中所定义; 其N-氧化物，其药学上可接受的盐或其溶剂合物; 条件是该化合物不是其或其药学上可接受的盐。 要求保护的化合物可用于治疗通过激活GHS1A-r受体而影响，介导或促进的疾病的治疗。 本发明还涉及其药物组合物及其制备方法。
-
公开(公告)号：US09040725B2
公开(公告)日：2015-05-26
申请号：US14202136
申请日：2014-03-10
Applicant: Janssen Pharmaceutica NV
Inventor： Bruno Schoentjes , Alain Philippe Poncelet , Julien Georges Pierre-Olivier Doyon , Joannes Theodorus Maria Linders , Lieven Meerpoel , Luc August Laurentius Ver Donck
IPC: C07D313/00 , C07C211/00 , C07C215/42 , C07C35/52 , C07C43/192 , C07C215/64 , C07C217/08 , C07C217/74 , C07D295/092 , C07D313/08 , C07D405/04 , C07D407/04 , C07D207/06 , C07D213/53 , C07D213/65 , C07D215/14 , C07D239/26 , C07D295/096 , C07D295/16 , C07D317/58
CPC classification number: C07C215/42 , C07C35/52 , C07C43/192 , C07C215/64 , C07C217/08 , C07C217/74 , C07C2602/12 , C07D207/06 , C07D213/53 , C07D213/65 , C07D215/14 , C07D239/26 , C07D295/092 , C07D295/096 , C07D295/16 , C07D313/08 , C07D317/58 , C07D405/04 , C07D407/04
Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.
Abstract translation: 本发明涉及包括其任何立体化学异构体形式的式（I）化合物，其中取代基如说明书和权利要求中所定义; 其N-氧化物，其药学上可接受的盐或其溶剂合物; 条件是该化合物不是其或其药学上可接受的盐。 要求保护的化合物可用于治疗通过激活GHS1A-r受体而影响，介导或促进的疾病的治疗。 本发明还涉及其药物组合物及其制备方法。
